# A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

> **NCT01652703** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 310 (actual)

## Conditions studied

- Hypercholesterolemia and High Risk for Cardiovascular Events

## Interventions

- **BIOLOGICAL:** Evolocumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01652703
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-10
- **Primary completion:** 2013-05-14
- **Final completion:** —
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2018-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652703, "A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01652703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*